Card image cap
Dupilumab induces eosinophilic esophagitis remission

Dupilumab effectively induced remission of esophageal esophagitis (EoE) among children with eosinophilic esophagitis treated with the agent for atopic conditions, showed a recent study published in the Annals of Allergy, Asthma and Allergy. The researchers said that they analysed 45 patients at the Children’s Hospital of Philadelphia and Rady Children’s Hospital-San Diego who were prescribed dupilumab for asthma, atopic dermatitis or nasal polyps and who had concomitant EoE. The team wrote that thirty-nine of the patient cohort treated with dupilumab for an approved indication met the criteria for clinical improvement of their atopic condition. The research team concluded that ​​overall histology in the study fell from 52.9 eos/hpf at baseline to 4.5 eos/hpf after treatment.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.

Supported by Koye Pharmaceuticals

Submit a Comment